[{"id":"edeab902-2100-4815-8330-db8677913ca6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05266950","created_at":"2022-03-04T15:53:28.701Z","updated_at":"2024-07-02T16:35:52.306Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05266950","lead_sponsor":"Beijing Boren Hospital","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 expression","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CI-135 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-03-27"}]